RZLT - Rezolute, Inc.

3.18
-0.030   -0.943%

Share volume: 1,365,180
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$3.21
-0.03
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
52%
Profitability 35%
Dept financing 27%
Liquidity 50%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.45%
1 Month
-12.40%
3 Months
76.67%
6 Months
-58.65%
1 Year
-15.43%
2 Year
63.08%
Key data
Stock price
$3.18
P/E Ratio 
0.00
DAY RANGE
$3.07 - $3.24
EPS 
-$0.94
52 WEEK RANGE
$1.07 - $11.46
52 WEEK CHANGE
-$14.97
MARKET CAP 
218.837 M
YIELD 
N/A
SHARES OUTSTANDING 
95.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
-0.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,574,820
AVERAGE 30 VOLUME 
$2,261,294
Company detail
CEO: Nevan C. Elam
Region: US
Website: rezolutebio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Recent news